From 35145955108e23d018f18c2c1170775e47da0eec Mon Sep 17 00:00:00 2001
From: gromdimon <grom.dima.grom@gmail.com>
Date: Wed, 15 Nov 2023 11:02:10 +0100
Subject: [PATCH] feat: new info in about page

---
 frontend/src/views/AboutView.vue | 48 ++++++++++++++++++++++++++++++--
 1 file changed, 45 insertions(+), 3 deletions(-)

diff --git a/frontend/src/views/AboutView.vue b/frontend/src/views/AboutView.vue
index c55691c1..e9ee91c4 100644
--- a/frontend/src/views/AboutView.vue
+++ b/frontend/src/views/AboutView.vue
@@ -51,9 +51,45 @@ const Acknowledgements: AcknowledgementsType = {
               researcher investigating rare diseases, REEV is here to streamline your workflow. Our
               platform combines cutting-edge technology with user-friendly interfaces to ensure that
               you have the resources you need to make informed decisions.
-            </p></v-card-text
-          ></v-card
-        >
+            </p>
+            <p class="subtitle">Sequence Variants in REEV</p>
+            <p class="description">
+              REEV's documentation on ACMG Sequence Variant Criteria provides a comprehensive guide
+              for the automated classification of sequence variants. This process emphasizes
+              transparency for users, ensuring they receive detailed reports of evidence supporting
+              or contradicting each criterion. It is meticulously designed to inform users why
+              certain criteria are applied or omitted in specific cases, such as when one criterion
+              may invalidate others due to the nature of the variant (e.g., BA1 disabling all other
+              benign criteria). In addition, the ACMG Sequence Variant Details section elaborates on
+              the implementation of these classification criteria. This includes a detailed
+              description of the data sources utilized in the classification of sequence variants.
+              These sources form the foundation of the classification process, aiding in the
+              accurate and comprehensive evaluation of sequence variants.
+            </p>
+            <p class="subtitle">Copy Number Variants in REEV</p>
+            <p class="description">
+              The ACMG CNV Criteria section in REEV's documentation outlines the implementation of
+              criteria for CNVs (Copy Number Variants), based on guidelines from Riggs et al.
+              (2020). These criteria are critical for understanding and classifying CNVs in the
+              context of genetic analysis and rare disease research. Furthermore, the ACMG CNV
+              Details page provides in-depth information about the assessment criteria for CNVs.
+              This includes an overview of the data used for classification, emphasizing the
+              thorough and detailed approach REEV takes in evaluating CNVs. The data used in this
+              classification process is pivotal for understanding the genetic implications of CNVs
+              and their potential impact on rare genetic disorders.
+            </p>
+            <p class="description">
+              Overall, REEV's approach to both sequence and CNV variants is characterized by a
+              meticulous and transparent methodology. The platform's use of comprehensive data
+              sources and adherence to established criteria ensures that it remains a valuable tool
+              for researchers and clinicians in the field of rare disease genetics.
+            </p>
+            <p class="description">
+              For more detailed information, please visit our
+              <a href="https://reev.readthedocs.io/en/latest/">documentation</a>.
+            </p>
+          </v-card-text>
+        </v-card>
       </v-col>
     </v-row>
     <v-row>
@@ -92,4 +128,10 @@ const Acknowledgements: AcknowledgementsType = {
   font-size: 16px;
   margin-bottom: 20px;
 }
+
+.subtitle {
+  font-size: 18px;
+  font-weight: bold;
+  margin-bottom: 10px;
+}
 </style>